论文部分内容阅读
目的以循证医学的方法对5％咪喹莫特乳膏治疗尖锐湿疣的疗效与安全性进行系统评价,方法检索PubMed、Ovid、Web of Science、UMI、Elsevier以及Cochrane图书馆、中文科技期刊数据库(CNKI)、中国生物医学文献数据库(CBMDisc),纳入比较5％咪喹莫特乳膏与安慰剂或氟尿嘧啶乳膏的随机对照试验,由两名评价者独立提取资料并进行方法学质量评估。试验数据的统计分析采用Cochrane协作网提供的RevMan 4．2．8软件进行。结果最终纳入8个临床随机对照试验,对5％咪喹莫特乳膏治疗尖锐湿疣进行了Meta分析,与安慰剂组相比,差异具有统计学意义;与氟尿嘧啶乳膏组相比,疗效差异无统计学意义,没有报道与5％咪喹莫特乳膏临床应用相关的严重系统性不良反应。结论现有临床证据表明,5％咪喹莫特乳膏治疗尖锐湿疣有确切的疗效与较好的安全性。
Objective To systematically evaluate the efficacy and safety of 5% imiquimod cream in the treatment of condyloma acuminatum by means of evidence-based medicine. Methods PubMed, Ovid, Web of Science, UMI, Elsevier and Cochrane Library, Chinese Journal of Science and Technology Database CNKI and CBMDisc were included in a randomized controlled trial comparing 5% imiquimod cream with placebo or fluorouracil cream. Two reviewers independently extracted data and assessed methodological quality. Statistical analysis of experimental data was performed using RevMan 4.2.8 software provided by the Cochrane Collaboration. The results were finally included in eight randomized controlled trials of 5% imiquimod cream treatment of genital warts Meta analysis, compared with the placebo group, the difference was statistically significant; compared with the fluorouracil cream group, the difference in efficacy Not statistically significant and no serious adverse systemic reactions associated with the clinical use of 5% imiquimod cream were reported. Conclusion The available clinical evidence shows that 5% imiquimod cream has the exact curative effect and good safety.